{"id":723,"date":"2026-09-01T15:21:54","date_gmt":"2026-09-01T15:21:54","guid":{"rendered":"https:\/\/nhdbio.com\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/"},"modified":"2026-09-01T15:32:23","modified_gmt":"2026-09-01T15:32:23","slug":"tirzepatide-surmount-1-2539-adults-72-weeks","status":"publish","type":"case_study","link":"https:\/\/nhdbio.com\/ja\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/","title":{"rendered":"Tirzepatide SURMOUNT-1: 2,539 \u6210\u4eba (72 \u9031\u9593\u4ee5\u4e0a)"},"content":{"rendered":"<h2>SURMOUNT-1 \u304c\u30a2\u30f3\u30ab\u30fc \u30b9\u30bf\u30c7\u30a3\u3068\u3057\u3066\u6709\u7528\u3067\u3042\u308b\u7406\u7531<\/h2>\n<p>SURMOUNT-1 \u306f\u3001\u30d7\u30e9\u30bb\u30dc\u7fa4\u3068\u4e8b\u524d\u306b\u6307\u5b9a\u3055\u308c\u305f\u5171\u4e3b\u8981\u8a55\u4fa1\u9805\u76ee\u3092\u7528\u3044\u305f\u5927\u898f\u6a21\u306a\u30e9\u30f3\u30c0\u30e0\u5316\u30d5\u30a7\u30fc\u30ba 3 \u8a66\u9a13\u3067\u3059\u3002\u3057\u305f\u304c\u3063\u3066\u3001\u30e1\u30ab\u30cb\u30ba\u30e0\u306e\u4e3b\u5f35\u3084\u7ba1\u7406\u3055\u308c\u3066\u3044\u306a\u3044\u89b3\u5bdf\u3088\u308a\u3082\u5f37\u529b\u306a\u81e8\u5e8a\u8a3c\u62e0\u306e\u8b70\u8ad6\u3092\u30b5\u30dd\u30fc\u30c8\u3057\u307e\u3059\u3002\u3053\u306e\u8ad6\u6587\u3067\u306f\u3001\u9078\u629e\u7684\u306b\u9078\u3070\u308c\u305f 1 \u3064\u306e\u6570\u3067\u306f\u306a\u304f\u3001\u30e9\u30f3\u30c0\u30e0\u5316\u3055\u308c\u305f\u7528\u91cf\u30b0\u30eb\u30fc\u30d7\u306e\u5b8c\u5168\u306a\u30bb\u30c3\u30c8\u3082\u5831\u544a\u3055\u308c\u3066\u3044\u307e\u3059\u3002<\/p>\n<h2>\u4eba\u53e3\u3068\u30a8\u30f3\u30c9\u30dd\u30a4\u30f3\u30c8<\/h2>\n<p>\u3053\u306e\u8a66\u9a13\u306b\u306f\u3001\u4f53\u91cd\u95a2\u9023\u306e\u5408\u4f75\u75c7\u3092\u4f34\u3046\u5c11\u306a\u304f\u3068\u308230\u3001\u307e\u305f\u306f\u5c11\u306a\u304f\u3068\u308227\u306eBMI\u3092\u6709\u3059\u308b\u6210\u4eba\u304c\u767b\u9332\u3055\u308c\u3001\u7cd6\u5c3f\u75c5\u306f\u9664\u5916\u3055\u308c\u305f\u3002\u53c2\u52a0\u8005\u306f\u30013\u3064\u306e\u30c1\u30eb\u30bc\u30d1\u30c1\u30c9\u7fa4\u307e\u305f\u306f\u30d7\u30e9\u30bb\u30dc\u7fa4\u306b\u5747\u7b49\u306b\u30e9\u30f3\u30c0\u30e0\u5316\u3055\u308c\u307e\u3057\u305f\u3002\u6cbb\u7642\u8a08\u753b\u63a8\u5b9a\u5024\u306f\u3001\u6cbb\u7642\u610f\u56f3\u306e\u3042\u308b\u96c6\u56e3\u306b\u304a\u3051\u308b\u6cbb\u7642\u4e2d\u6b62\u306b\u95a2\u4fc2\u306a\u304f\u8ee2\u5e30\u3092\u8a55\u4fa1\u3057\u307e\u3057\u305f\u3002<\/p>\n<h2>\u30b3\u30f3\u30c6\u30ad\u30b9\u30c8\u5185\u306e\u7d50\u679c<\/h2>\n<p>3 \u3064\u306e\u30c1\u30eb\u30bc\u30d1\u30c1\u30c9\u7fa4\u306f\u3059\u3079\u3066\u3001\u5831\u544a\u3055\u308c\u305f\u4f53\u91cd\u30a8\u30f3\u30c9\u30dd\u30a4\u30f3\u30c8\u306b\u95a2\u3057\u3066\u30d7\u30e9\u30bb\u30dc\u3068\u306f\u7570\u306a\u308a\u307e\u3057\u305f\u3002\u3053\u306e\u8ad6\u6587\u3067\u306f\u307e\u305f\u3001\u80c3\u8178\u306e\u6709\u5bb3\u4e8b\u8c61\u304c\u6700\u3082\u4e00\u822c\u7684\u3067\u3042\u308a\u3001\u4e00\u822c\u306b\u30a8\u30b9\u30ab\u30ec\u30fc\u30b7\u30e7\u30f3\u4e2d\u306b\u5831\u544a\u3055\u308c\u3066\u304a\u308a\u3001\u30e9\u30f3\u30c0\u30e0\u5316\u3055\u308c\u305f\u5404\u30b0\u30eb\u30fc\u30d7\u306e\u4e2d\u6b62\u7387\u3082\u63d0\u4f9b\u3055\u308c\u3066\u3044\u307e\u3059\u3002\u3053\u308c\u3089\u306e\u5206\u6bcd\u3068\u6709\u5bb3\u4e8b\u8c61\u30c7\u30fc\u30bf\u3092\u53ef\u8996\u5316\u3057\u3066\u304a\u304f\u3053\u3068\u3067\u3001\u6709\u52b9\u6027\u306e\u307f\u306e\u8981\u7d04\u3092\u9632\u3050\u3053\u3068\u304c\u3067\u304d\u307e\u3059\u3002<\/p>\n<div class=\"pfm-case-callout\"><strong>\u6bd4\u8f03\u5883\u754c:<\/strong> SURMOUNT-1 \u306f\u30ec\u30bf\u30c8\u30eb\u30c1\u30c9\u8a66\u9a13\u3067\u306f\u306a\u3044\u305f\u3081\u3001Retatrutide \u5bfe Tirzepatide \u306e\u76f4\u63a5\u7684\u306a\u30e9\u30f3\u30ad\u30f3\u30b0\u3092\u63d0\u4f9b\u3059\u308b\u3053\u3068\u306f\u3067\u304d\u307e\u305b\u3093\u3002\u30af\u30ed\u30b9\u30c8\u30e9\u30a4\u30a2\u30eb\u306e\u30d1\u30fc\u30bb\u30f3\u30c6\u30fc\u30b8\u306f\u3001\u3055\u307e\u3056\u307e\u306a\u30d7\u30ed\u30c8\u30b3\u30eb\u3068\u958b\u767a\u6bb5\u968e\u304b\u3089\u5f97\u3089\u308c\u307e\u3059\u3002<\/div>\n<h2>\u5b8c\u6210\u54c1\u306e\u533a\u5225<\/h2>\n<p>\u898f\u5236\u5f53\u5c40\u304c\u5be9\u67fb\u3057\u305f\u5b8c\u6210\u54c1\u306e\u533b\u85ac\u54c1\u304b\u3089\u306e\u81e8\u5e8a\u8ee2\u5e30\u306f\u3001\u540d\u524d\u306f\u540c\u3058\u3067\u3082\u540c\u3058\u51e6\u65b9\u3001\u9001\u9054\u30b7\u30b9\u30c6\u30e0\u3001\u653e\u51fa\u4ed5\u69d8\u3001\u54c1\u8cea\u7ba1\u7406\u304c\u6b20\u5982\u3057\u3066\u3044\u308b\u6750\u6599\u306b\u8ee2\u7528\u3059\u308b\u3053\u3068\u306f\u3067\u304d\u307e\u305b\u3093\u3002\u3053\u306e\u533a\u5225\u306f\u8a3c\u62e0\u8a18\u9332\u306e\u4e00\u90e8\u3067\u3042\u308a\u3001\u811a\u6ce8\u3067\u306f\u3042\u308a\u307e\u305b\u3093\u3002<\/p>","protected":false},"excerpt":{"rendered":"<p>SURMOUNT-1 \u76f8 3 \u8a66\u9a13\u306e\u69cb\u9020\u5316\u3055\u308c\u305f\u8aad\u307f\u53d6\u308a\u3002\u30e9\u30f3\u30c0\u30e0\u5316\u30c7\u30b6\u30a4\u30f3\u30014 \u30b0\u30eb\u30fc\u30d7\u306e\u7d50\u679c\u3001\u4e2d\u6b62\u30c7\u30fc\u30bf\u3001\u304a\u3088\u3073\u627f\u8a8d\u3055\u308c\u305f\u5b8c\u6210\u54c1\u3068\u7814\u7a76\u7528\u6750\u6599\u306e\u533a\u5225\u304c\u4fdd\u5b58\u3055\u308c\u3066\u3044\u307e\u3059\u3002<\/p>","protected":false},"author":0,"featured_media":851,"template":"","class_list":["post-723","case_study","type-case_study","status-publish","has-post-thumbnail","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.0 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Tirzepatide SURMOUNT-1 Trial: 2,539 Adults<\/title>\n<meta name=\"description\" content=\"A structured reading of the SURMOUNT-1 Phase 3 trial, preserving the randomized design, four-group results, discontinuation data and the distinction between an approved finished drug and research-use material.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/ja\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tirzepatide SURMOUNT-1: 2,539 Adults Over 72 Weeks\" \/>\n<meta property=\"og:description\" content=\"A structured reading of the SURMOUNT-1 Phase 3 trial, preserving the randomized design, four-group results, discontinuation data and the distinction between an approved finished drug and research-use material.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/ja\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-01T15:32:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/tirzepatide-surmount-1-editorial-v2.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1672\" \/>\n\t<meta property=\"og:image:height\" content=\"941\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data1\" content=\"1\u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/tirzepatide-surmount-1-2539-adults-72-weeks\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/tirzepatide-surmount-1-2539-adults-72-weeks\\\/\",\"name\":\"Tirzepatide SURMOUNT-1 Trial: 2,539 Adults\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/tirzepatide-surmount-1-2539-adults-72-weeks\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/tirzepatide-surmount-1-2539-adults-72-weeks\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/tirzepatide-surmount-1-editorial-v2.webp\",\"datePublished\":\"2026-09-01T15:21:54+00:00\",\"dateModified\":\"2026-09-01T15:32:23+00:00\",\"description\":\"A structured reading of the SURMOUNT-1 Phase 3 trial, preserving the randomized design, four-group results, discontinuation data and the distinction between an approved finished drug and research-use material.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/tirzepatide-surmount-1-2539-adults-72-weeks\\\/#breadcrumb\"},\"inLanguage\":\"ja\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/tirzepatide-surmount-1-2539-adults-72-weeks\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/tirzepatide-surmount-1-2539-adults-72-weeks\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/tirzepatide-surmount-1-editorial-v2.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/tirzepatide-surmount-1-editorial-v2.webp\",\"width\":1672,\"height\":941,\"caption\":\"Editorial research illustration; not a photograph of trial participants or an actual study site.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/tirzepatide-surmount-1-2539-adults-72-weeks\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u6848\u4f8b\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Tirzepatide SURMOUNT-1: 2,539 Adults Over 72 Weeks\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ja\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Tirzepatide SURMOUNT-1 \u30c8\u30e9\u30a4\u30a2\u30eb: 2,539 \u6210\u4eba","description":"SURMOUNT-1 \u76f8 3 \u8a66\u9a13\u306e\u69cb\u9020\u5316\u3055\u308c\u305f\u8aad\u307f\u53d6\u308a\u3002\u30e9\u30f3\u30c0\u30e0\u5316\u30c7\u30b6\u30a4\u30f3\u30014 \u30b0\u30eb\u30fc\u30d7\u306e\u7d50\u679c\u3001\u4e2d\u6b62\u30c7\u30fc\u30bf\u3001\u304a\u3088\u3073\u627f\u8a8d\u3055\u308c\u305f\u5b8c\u6210\u54c1\u3068\u7814\u7a76\u7528\u6750\u6599\u306e\u533a\u5225\u304c\u4fdd\u5b58\u3055\u308c\u3066\u3044\u307e\u3059\u3002","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/ja\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/","og_locale":"ja_JP","og_type":"article","og_title":"Tirzepatide SURMOUNT-1: 2,539 Adults Over 72 Weeks","og_description":"A structured reading of the SURMOUNT-1 Phase 3 trial, preserving the randomized design, four-group results, discontinuation data and the distinction between an approved finished drug and research-use material.","og_url":"https:\/\/nhdbio.com\/ja\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/","og_site_name":"NHD","article_modified_time":"2026-09-01T15:32:23+00:00","og_image":[{"width":1672,"height":941,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/tirzepatide-surmount-1-editorial-v2.webp","type":"image\/webp"}],"twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"1\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/","url":"https:\/\/nhdbio.com\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/","name":"Tirzepatide SURMOUNT-1 \u30c8\u30e9\u30a4\u30a2\u30eb: 2,539 \u6210\u4eba","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/tirzepatide-surmount-1-editorial-v2.webp","datePublished":"2026-09-01T15:21:54+00:00","dateModified":"2026-09-01T15:32:23+00:00","description":"SURMOUNT-1 \u76f8 3 \u8a66\u9a13\u306e\u69cb\u9020\u5316\u3055\u308c\u305f\u8aad\u307f\u53d6\u308a\u3002\u30e9\u30f3\u30c0\u30e0\u5316\u30c7\u30b6\u30a4\u30f3\u30014 \u30b0\u30eb\u30fc\u30d7\u306e\u7d50\u679c\u3001\u4e2d\u6b62\u30c7\u30fc\u30bf\u3001\u304a\u3088\u3073\u627f\u8a8d\u3055\u308c\u305f\u5b8c\u6210\u54c1\u3068\u7814\u7a76\u7528\u6750\u6599\u306e\u533a\u5225\u304c\u4fdd\u5b58\u3055\u308c\u3066\u3044\u307e\u3059\u3002","breadcrumb":{"@id":"https:\/\/nhdbio.com\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/nhdbio.com\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/tirzepatide-surmount-1-editorial-v2.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/tirzepatide-surmount-1-editorial-v2.webp","width":1672,"height":941,"caption":"Editorial research illustration; not a photograph of trial participants or an actual study site."},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"\u6848\u4f8b","item":"https:\/\/nhdbio.com\/case-studies\/"},{"@type":"ListItem","position":3,"name":"Tirzepatide SURMOUNT-1: 2,539 Adults Over 72 Weeks"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"\u30da\u30d7\u30c1\u30c9\u539f\u6599\u30fb\u30ab\u30b9\u30bf\u30e0\u30da\u30d7\u30c1\u30c9\u5408\u6210","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/ja\/wp-json\/wp\/v2\/case_study\/723","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/ja\/wp-json\/wp\/v2\/case_study"}],"about":[{"href":"https:\/\/nhdbio.com\/ja\/wp-json\/wp\/v2\/types\/case_study"}],"version-history":[{"count":1,"href":"https:\/\/nhdbio.com\/ja\/wp-json\/wp\/v2\/case_study\/723\/revisions"}],"predecessor-version":[{"id":728,"href":"https:\/\/nhdbio.com\/ja\/wp-json\/wp\/v2\/case_study\/723\/revisions\/728"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/ja\/wp-json\/wp\/v2\/media\/851"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/ja\/wp-json\/wp\/v2\/media?parent=723"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}